Xuezhikang Capsule for Type 2 Diabetes with Hyperlipemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trails

Table 2

The result of the continuous variables.

Study	Intervention	Dosage	Treatment	TC	TG	HDL-C	LDL-C
Liao and Chen 2010 [7]	XZK + BGLD	0.6 g/time bid	Before	6.98 ± 0.67	2.02 ± 0.35	1.05 ± 0.11	3.92 ± 0.42
			After	4.45 ± 0.43	1.67 ± 0.40	1.24 ± 0.19	2.67 ± 0.48
	Simvastatin + BGLD	20 mg/time qd	Before	6.85 ± 0.52	2.31 ± 0.36	1.06 ± 0.13	3.76 ± 0.24
			After	4.65 ± 0.42	1.91 ± 0.62	1.17 ± 0.13	2.75 ± 0.42
Liu and Dong 2008 [8]	XZK + BGLD	0.6 g/time bid	Before	5.97 ± 0.38	2.53 ± 0.35	1.04 ± 0.12	3.94 ± 0.43
			After	4.46 ± 0.42	1.65 ± 0.39	1.23 ± 0.18	2.67 ± 0.47
	Simvastatin + BGLD	10 mg/time qd	Before	6.03 ± 0.45	2.49 ± 0.36	1.09 ± 0.16	3.78 ± 0.46
			After	4.68 ± 0.43	1.84 ± 0.51	1.16 ± 0.14	2.75 ± 0.43
Wang et al. 2005 [9]	XZK + BGLD	0.6 g/time bid	Before	6.8 ± 1.9	3.4 ± 1.2	1.2 ± 0.5	3.9 ± 1.5
			After	4.5 ± 1.6	2.2 ± 0.9	1.4 ± 0.6	2.5 ± 1.3
	Pravastatin + BGLD	20 mg/d	Before	6.7 ± 1.2	3.3 ± 1.1	1.1 ± 0.4	4.1 ± 1.1
			After	4.4 ± 1.0	2.1 ± 0.8	1.3 ± 0.7	2.6 ± 1.5
	XZK + BGLD	0.6 g/time bid	Before	6.8 ± 1.9	3.4 ± 1.2	1.2 ± 0.5	3.9 ± 1.5
			After	4.5 ± 1.6	2.2 ± 0.9	1.4 ± 0.6	2.5 ± 1.3
	Fenofibrate + BGLD	0.2 g/time qd	Before	6.8 ± 0.9	3.3 ± 0.9	1.2 ± 0.6	3.9 ± 1.2
			After	5.2 ± 1.2	1.7 ± 0.7	1.5 ± 0.8	3.2 ± 1.4
Lanfan and Zurong 2005 [10]	XZK + BGLD	0.6 g/time bid	Before	6.86 ± 0.62	3.49 ± 1.15	0.88 ± 0.14	4.15 ± 1.05
			After	4.81 ± 1.18	2.18 ± 0.55	1.13 ± 0.22	2.88 ± 1.01
	Simvastatin + BGLD	10–20/time qd	Before	6.91 ± 0.68	3.32 ± 1.16	0.87 ± 0.13	4.13 ± 1.02
			After	4.76 ± 1.19	2.15 ± 0.56	1.06 ± 0.21	2.69 ± 1.03
Tong 2012 [11]	XZK + BGLD	0.6 g/time bid	Before	6.24 ± 1.52	3.11 ± 1.28	1.06 ± 0.24	4.32 ± 1.27
			After	4.54 ± 1.14	2.11 ± 1.24	1.65 ± 0.28	3.11 ± 1.13
	Simvastatin + BGLD	20/time qd	Before	6.26 ± 1.50	3.14 ± 1.61	1.06 ± 0.38	4.36 ± 1.22
			After	4.95 ± 1.46	2.71 ± 1.20	1.62 ± 0.24	2.45 ± 1.07
Zhe 2012 [12]	XZK + BGLD	0.6 g/time bid	Before	6.55 ± 1.09	2.11 ± 0.34	1.05 ± 0.11	3.89 ± 0.43
			After	4.53 ± 0.49	1.42 ± 0.21	1.34 ± 0.15	2.56 ± 0.51
	Atorvastatin + BGLD	10 mg/time qd	Before	6.78 ± 0.79	2.30 ± 0.41	1.01 ± 0.14	3.77 ± 0.35
			After	4.87 ± 0.55	1.96 ± 0.42	1.12 ± 0.09	2.93 ± 0.28
Xueling 2007 [13]	XZK + BGLD	0.6 g/time bid	Before	6.79 ± 1.50	3.38 ± 1.52	1.01 ± 0.22	4.20 ± 1.30
			After	5.51 ± 1.22	2.12 ± 1.27	1.98 ± 0.38	2.65 ± 1.10
	Fluvastatin + BGLD	40 mg/time qd	Before	6.82 ± 1.54	3.41 ± 1.82	1.07 ± 0.26	4.25 ± 1.20
			After	5.45 ± 1.42	2.42 ± 1.10	2.24 ± 0.59	2.20 ± 1.18
Chen 2013 [14]	XZK + BGLD	0.6 g/time bid	Before	5.90 ± 1.12	2.81 ± 1.21	0.98 ± 0.43	3.85 ± 0.86
			After	3.93 ± 0.89	1.89 ± 1.13	1.39 ± 0.51	2.6 ± 0.78
	Simvastatin + BGLD	20 mg/time qd	Before	5.87 ± 1.38	2.37 ± 0.98	1.01 ± 0.35	3.73 ± 0.67
			After	4.00 ± 0.93	1.90 ± 1.15	1.37 ± 0.54	2.47 ± 0.93
Yang 2008 [15]	XZK + BGLD	0.6 g/time bid	Before	6.23 ± 1.51	3.12 ± 1.42	1.07 ± 0.22	4.36 ± 1.22
			After	4.53 ± 1.12	2.12 ± 1.20	1.63 ± 0.31	3.10 ± 1.12
	Simvastatin + BGLD	20 mg/time qd	Before	6.27 ± 1.49	3.13 ± 1.62	1.08 ± 0.35	4.37 ± 1.21
			After	4.94 ± 1.45	2.72 ± 1.19	1.59 ± 0.28	2.47 ± 1.03
Jianhui 2013 [16]	XZK + BGLD	0.6 g/time bid	Before	6.7 ± 1.3	2.2 ± 0.4	1.1 ± 0.2	3.9 ± 0.7
			After	4.6 ± 0.7	1.4 ± 0.3	1.4 ± 0.1	2.7 ± 0.3
	Rosuvastatin + BGLD	10 mg/time qd	Before	6.9 ± 1.0	2.3 ± 0.6	1.0 ± 0.1	3.8 ± 0.5
			After	5.1 ± 0.4	1.9 ± 0.4	1.1 ± 0.2	3.0 ± 0.3
Hui and Zhaoliang 2005 [17]	XZK + BGLD	0.6 g/time bid	Before	6.2 ± 1.5	3.15 ± 1.52	1.06 ± 0.23	4.53 ± 1.23
			After	4.5 ± 1.2	2.16 ± 1.25	1.62 ± 0.38	3.09 ± 1.15
	Simvastatin + BGLD	20 mg/time qd	Before	6.3 ± 1.5	3.16 ± 1.82	1.08 ± 0.36	4.38 ± 1.19
			After	4.9 ± 1.8	2.71 ± 1.09	1.19 ± 0.27	2.48 ± 1.02
Zhang and Chen 2010 [19]	XZK + BGLD		Before	6.55 ± 0.32	2.81 ± 0.46	1.15 ± 1.4	3.85 ± 0.71
		0.6 g/time bid	After	5.13 ± 0.51	1.54 ± 0.38	1.4 ± 0.25	2.75 ± 0.29
	BGLD		Before	6.71 ± 0.41	2.96 ± 0.55	1.17 ± 0.31	3.93 ± 0.82
			After	6.45 ± 0.73	2.87 ± 0.49	1.18 ± 0.78	3.91 ± 0.97
Tang and Weng 2002 [18]	XZK + BGLD		Before	6.06 ± 2.35	3.14 ± 1.82	0.95 ± 0.42
		0.6 g/time bid	After	4.89 ± 1.81	1.71 ± 0.73	1.3 ± 0.45
	BGLD		Before	6.1 ± 2.62	3.3 ± 0.9	0.91 ± 0.27
			After	6.06 ± 2.35	3.2 ± 0.5	0.95 ± 0.42
Yang et al. 2013 [20]	XZK + BGLD		Before	5.86 ± 1.14	2.6 ± 1.01	0.94 ± 0.2	3.39 ± 1.22
		0.6 g/time bid	After	5 ± 0.68	1.73 ± 0.92	1.1 ± 0.17	2.56 ± 0.91
	BGLD		Before	5.81 ± 0.75	2.64 ± 1.12	0.97 ± 0.24	2.92 ± 0.57
			After	5.63 ± 0.91	2.49 ± 0.86	1.05 ± 0.19	2.8 ± 0.35
Tongcui and Bihui 2002 [21]	XZK + BGLD		Before	6.6 ± 0.3	3.1 ± 0.85	1.2 ± 0.1	3.7 ± 0.3
		0.6 g/time bid	After	5.6 ± 0.3	1.6 ± 0.2	1.4 ± 0.2	2.6 ± 0.3
	BGLD		Before	6.4 ± 0.4	2.9 ± 0.4	1.1 ± 0.1	3.8 ± 0.2
			After	6.4 ± 0.3	2.1 ± 0.5	1.2 ± 0.1	3.7 ± 0.1
Tongcui and Bihui 2002 [21]	XZK + BGLD		Before	6.6 ± 0.3	3.1 ± 0.85	1.2 ± 0.1	3.7 ± 0.3
		0.6 g/time bid	After	5.3 ± 0.2	1.4 ± 0.3	1.6 ± 0.1	2.4 ± 0.3
	BGLD		Before	6.4 ± 0.4	2.9 ± 0.4	1.1 ± 0.1	3.8 ± 0.2
			After	6.4 ± 0.3	2.1 ± 0.4	1.3 ± 0.2	3.5 ± 0.3
Chen 2004 [24]	XZK + BGLD		Before	8.12 ± 0.81	2.16 ± 0.98	1.03 ± 0.52	4.46 ± 0.93
		0.6 g/time bid	After	4.51 ± 0.95	1.18 ± 0.83	2.42 ± 0.56	2.50 ± 0.89
	Placebo + BGLD		Before	7.98 ± 0.87	2.14 ± 0.86	1.06 ± 0.49	4.48 ± 0.95
			After	7.55 ± 0.88	2.17 ± 0.98	1.08 ± 0.53	4.39 ± 0.97